Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review.
DNA repair
biomarker
colorectal cancer
hyperthermic intraperitoneal chemotherapy
mitomycin C
oxaliplatin
treatment outcome
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
06
2020
accepted:
27
08
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
The introduction of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with either oxaliplatin or mitomycin C for patients with colorectal peritoneal metastasis (CPM) has resulted in a major increase in overall survival. Nonetheless, despite critical patient selection, the majority of patients will develop recurrent disease within one year following CRS + HIPEC. Therefore, improvement of patient and treatment selection is needed and may be achieved by the incorporation of genetic biomarkers. This systematic review aims to provide an overview of genetic biomarkers in the DNA repair pathway that are potentially predictive for treatment outcome of patients with colorectal peritoneal metastases treated with CRS + HIPEC with oxaliplatin or mitomycin C. A systematic review was conducted according to the PRISMA guidelines. Given the limited number of genetic association studies of intraperitoneal mitomycin C and oxaliplatin in patients with CPM, we expanded the review and extrapolated the data from biomarker studies conducted in colorectal cancer patients treated with systemic mitomycin C- and oxaliplatin-based chemotherapy. In total, 43 papers were included in this review. No study reported potential pharmacogenomic biomarkers in patients with colorectal cancer undergoing mitomycin C-based chemotherapy. For oxaliplatin-based chemotherapy, a total of 26 genetic biomarkers within 14 genes were identified that were significantly associated with treatment outcome. The most promising genetic biomarkers were Several genetic biomarkers have proven predictive value for the treatment outcome of systemically administered oxaliplatin. By extrapolation, these genetic biomarkers may also be predictive for the efficacy of intraperitoneal oxaliplatin. This should be the subject of further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
The introduction of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with either oxaliplatin or mitomycin C for patients with colorectal peritoneal metastasis (CPM) has resulted in a major increase in overall survival. Nonetheless, despite critical patient selection, the majority of patients will develop recurrent disease within one year following CRS + HIPEC. Therefore, improvement of patient and treatment selection is needed and may be achieved by the incorporation of genetic biomarkers. This systematic review aims to provide an overview of genetic biomarkers in the DNA repair pathway that are potentially predictive for treatment outcome of patients with colorectal peritoneal metastases treated with CRS + HIPEC with oxaliplatin or mitomycin C.
METHODS
METHODS
A systematic review was conducted according to the PRISMA guidelines. Given the limited number of genetic association studies of intraperitoneal mitomycin C and oxaliplatin in patients with CPM, we expanded the review and extrapolated the data from biomarker studies conducted in colorectal cancer patients treated with systemic mitomycin C- and oxaliplatin-based chemotherapy.
RESULTS
RESULTS
In total, 43 papers were included in this review. No study reported potential pharmacogenomic biomarkers in patients with colorectal cancer undergoing mitomycin C-based chemotherapy. For oxaliplatin-based chemotherapy, a total of 26 genetic biomarkers within 14 genes were identified that were significantly associated with treatment outcome. The most promising genetic biomarkers were
CONCLUSION
CONCLUSIONS
Several genetic biomarkers have proven predictive value for the treatment outcome of systemically administered oxaliplatin. By extrapolation, these genetic biomarkers may also be predictive for the efficacy of intraperitoneal oxaliplatin. This should be the subject of further investigation.
Identifiants
pubmed: 33117169
doi: 10.3389/fphar.2020.577968
pmc: PMC7575928
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
577968Informations de copyright
Copyright © 2020 Hulshof, Lim, de Hingh, Gelderblom, Guchelaar and Deenen.
Références
Adv Clin Exp Med. 2019 Nov;28(11):1459-1468
pubmed: 31756062
Cancer Res. 2001 Dec 15;61(24):8654-8
pubmed: 11751380
Mol Carcinog. 2012 Oct;51 Suppl 1:E83-93
pubmed: 22213216
BMC Gastroenterol. 2014 Aug 29;14:154
pubmed: 25175730
Langenbecks Arch Surg. 2013 Jun;398(5):745-9
pubmed: 23456355
Cancer Chemother Pharmacol. 2010 Sep;66(4):659-67
pubmed: 20033812
Br J Cancer. 2009 Sep 15;101(6):998-1004
pubmed: 19672255
Mol Cell. 2013 May 9;50(3):333-43
pubmed: 23623683
Ann Surg. 2009 Jun;249(6):900-7
pubmed: 19474692
Cell. 1996 Sep 6;86(5):811-22
pubmed: 8797827
Pharmacogenomics J. 2016 Jun;16(3):272-9
pubmed: 26261061
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Surg Oncol. 2014 Jun;109(8):841-7
pubmed: 24619813
Pharmacogenomics J. 2015 Dec;15(6):505-12
pubmed: 25778469
Pharmacogenomics. 2011 Mar;12(3):433-42
pubmed: 21449681
J Natl Cancer Inst. 2014 Jan;106(1):djt322
pubmed: 24273214
J Clin Oncol. 2007 Apr 1;25(10):1247-54
pubmed: 17401013
Oncotarget. 2019 Sep 17;10(53):5510-5522
pubmed: 31565185
Cancer. 1989 Jan 15;63(2):364-7
pubmed: 2910444
Mol Cell Biol. 2008 Aug;28(16):5082-92
pubmed: 18541667
Oncology. 2007;72(5-6):364-70
pubmed: 18204222
Mol Cancer Ther. 2008 Jan;7(1):10-8
pubmed: 18187810
PLoS One. 2012;7(11):e50701
pubmed: 23209813
Mol Diagn Ther. 2011 Oct 1;15(5):277-83
pubmed: 21958378
Pharmacogenomics. 2007 Dec;8(12):1693-703
pubmed: 18085999
J Clin Oncol. 2001 Dec 1;19(23):4298-304
pubmed: 11731512
Pharmacogenet Genomics. 2011 Jan;21(1):18-25
pubmed: 21057378
Br J Cancer. 2008 Oct 7;99(7):1050-5
pubmed: 18797464
Br J Cancer. 2013 Jan 15;108(1):115-20
pubmed: 23175150
Mutat Res. 2014 Jan;759:37-44
pubmed: 24220697
J Clin Oncol. 2003 Oct 15;21(20):3737-43
pubmed: 14551293
Cell Cycle. 2010 Jan 1;9(1):90-6
pubmed: 20016270
Asian Pac J Cancer Prev. 2014;15(22):9699-706
pubmed: 25520091
Br J Clin Pharmacol. 2010 Jan;69(1):58-66
pubmed: 20078613
Cancer Res Treat. 2019 Oct;51(4):1518-1526
pubmed: 30913862
Cancer Sci. 2009 Jul;100(7):1261-6
pubmed: 19432884
Asian Pac J Cancer Prev. 2012;13(7):3465-9
pubmed: 22994779
Cancer Sci. 2010 Feb;101(2):530-5
pubmed: 19922504
Cancer Manag Res. 2017 Jun 30;9:259-266
pubmed: 28721098
Am J Surg. 2017 Feb;213(2):377-387
pubmed: 27816197
J Surg Oncol. 2016 Aug;114(2):222-7
pubmed: 27173150
EMBO J. 1990 May;9(5):1437-47
pubmed: 2184031
Cell. 1995 Mar 24;80(6):859-68
pubmed: 7697716
Eur J Cancer. 2008 Jun;44(9):1229-37
pubmed: 18448328
Ann Surg. 2016 Jun;263(6):1102-11
pubmed: 26756756
Cancer Manag Res. 2018 Dec 27;11:285-297
pubmed: 30643454
Ann Surg. 1995 Jan;221(1):29-42
pubmed: 7826158
EMBO J. 2003 Oct 15;22(20):5612-21
pubmed: 14532133
Cancer Sci. 2009 Feb;100(2):278-83
pubmed: 19068092
Nat Rev Cancer. 2003 Mar;3(3):155-68
pubmed: 12612651
Clin Cancer Res. 2011 Mar 15;17(6):1632-40
pubmed: 21278243
Oncol Lett. 2013 Sep;6(3):648-654
pubmed: 24137384
Br J Cancer. 2009 Jul 21;101(2):357-62
pubmed: 19536092
Ann Surg. 2013 Jun;257(6):1065-71
pubmed: 23299520
Mol Cell. 2010 Jul 30;39(2):247-58
pubmed: 20670893
Cancer Treat Rev. 2005 Apr;31(2):90-105
pubmed: 15847979
Onco Targets Ther. 2015 Mar 16;8:641-8
pubmed: 25834456
Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1925-1931
pubmed: 32354538
Int J Cancer. 2011 Jun 1;128(11):2717-25
pubmed: 20715167
Br J Cancer. 2004 Jul 19;91(2):344-54
pubmed: 15213713
Exp Mol Pathol. 2017 Feb;102(1):78-85
pubmed: 28088319
Br J Surg. 2002 Dec;89(12):1545-50
pubmed: 12445064
Ann Surg Oncol. 2016 May;23(5):1468-73
pubmed: 26572754
Clin Cancer Res. 2018 Oct 1;24(19):4745-4753
pubmed: 29921730
Cancer. 2017 Nov 15;123(22):4506-4514
pubmed: 28708932
Sci Rep. 2019 Jul 22;9(1):10572
pubmed: 31332257
Mutagenesis. 2015 May;30(3):441-9
pubmed: 25690281
J Cancer Res Clin Oncol. 2010 Aug;136(8):1135-42
pubmed: 20091185
J Cancer. 2014 May 02;5(6):425-32
pubmed: 24847383
EMBO J. 1997 Mar 3;16(5):1093-102
pubmed: 9118947
Nat Chem Biol. 2011 Apr 13;7(7):428-30
pubmed: 21490603
Oncol Rep. 2016 Mar;35(3):1349-55
pubmed: 26676960
Medicine (Baltimore). 2016 May;95(19):e3652
pubmed: 27175691
Pharmacogenomics. 2016 Oct;17(15):1725-1732
pubmed: 27636246
Clin Colorectal Cancer. 2018 Dec;17(4):280-284
pubmed: 30042009
Nature. 1993 Jun 10;363(6429):558-61
pubmed: 8505985
Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500
pubmed: 19960344
Jpn J Clin Oncol. 2013 Nov;43(11):1080-6
pubmed: 23999770
Ann Surg Oncol. 2006 Nov;13(11):1379-85
pubmed: 17009149
Clin Cancer Res. 2004 Mar 15;10(6):2158-67
pubmed: 15041737
J Mol Diagn. 2009 May;11(3):238-47
pubmed: 19324997
Pharmacogenomics J. 2018 Sep;18(5):623-632
pubmed: 29925895
Asian Pac J Cancer Prev. 2012;13(11):5721-4
pubmed: 23317245
J Clin Oncol. 2008 Jun 20;26(18):2952-8
pubmed: 18565881
Mol Cell. 1998 Aug;2(2):223-32
pubmed: 9734359